Androgen Abuse in Sport: International and National Anti-Androgen Programs

  • D. H. Catlin
Part of the Mineralogical Society Series book series (ENDO, volume 5)


The misuse of anabolic androgenic steroids for the purpose of enhancing performance continues to be a difficult problem for major sport organizations. After nearly fifteen years of education, research, and testing there is still ample evidence that the problem has not been effectively solved. The roots of the problem lie somewhere in the psychology, sociology, and economics of sport. Athletes are not drug users by nature and the point of the drugs is not to obtain a high, it is to enhance performance and win. Athletes are placed in an approach-avoidance conflict, the public expects them to win and rewards the winners, and they are expected to play fair. Many do play fair, but the ones that choose to cheat erode the fundamental value of sport.


Anabolic Steroid Carbon Isotope Ratio Anabolic Androgenic Steroid National Football League International Olympic Committee 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aguilera R, Becchi M, Casablanca H, Hatton CK, Catlin DH, Starcevic B, et al. Improved method of detection of testosterone abuse by gas chromatography/combustion/isotope ratio mass spectrometry analysis of urinary steroids. J Mass Spectrometry 1996;31:169–176.CrossRefGoogle Scholar
  2. Baenziger J, Bowers L. Variability of T/E ratios in athletes. In: Donike M, Geyer H, Gotzmann, eds. Proceedings of the 11th Cologne workshop on dope analysis, 7–12 March 1993. Edition Sport, Köln: Sport und Buch Strauss, 1994;41–52.Google Scholar
  3. Becchi M, Aguilera R, Farizon Y, Flament MM, Casabianca H, James P. Gas chromatography/combustion/isotope-ratio mass spectrometry analysis of urinary steroids to detect misuse of testosterone in sport. Rapid Commun Mass Spectrom. 1994;8:304–308.PubMedCrossRefGoogle Scholar
  4. Bjorkhem I, Lantto O, Lof A. Detection and quantitation of methandienone (Dianabol) in urine by isotope dilution—mass fragmentography. J Steroid Biochem. 1980;13:169–175.PubMedCrossRefGoogle Scholar
  5. Bjorkhem I, Ek H, Lantto O. Assay of ethylestrenol in urine by isotope dilution—mass spectrometry. J Chromatogr. 1982;232:154–159.PubMedCrossRefGoogle Scholar
  6. Bjorkhem I, Ek H. Detection and quantitation of 3 alpha-hydroxy-l-methylen-5 alpha-androstan-17-one, the major urinary metabolite of methenolone acetate (Primobolan) by isotope dilution—mass spectrometry. J Steroid Biochem. 1983;18:481–487.PubMedCrossRefGoogle Scholar
  7. Bowers LD, Analytical advances in detection of performance-enhancing compounds. Clin Chem. 1997;43:1299–1304.PubMedGoogle Scholar
  8. Brooks RV, Jeremiah G, Webb WA, Wheeler M. Detection of anabolic steroid administration to athletes. J Steroid Biochem. 1979;11:913–917.PubMedCrossRefGoogle Scholar
  9. Buckley WE, Yesalis CE, Friedl KE, et al. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA 1988;260:3441–3445.PubMedCrossRefGoogle Scholar
  10. Camacho AM, Migeon CJ. Studies on the origin of testosterone in the urine of normal adult subjects and patients with various endocrine disorders. J Clin Invest. 1964;43:1083–1089.PubMedGoogle Scholar
  11. Carlstrom K, Palonek E, Garle M, Oftebro H, Stanghelle J, Bjorkhem I. Detection of testosterone administration by increased ratio between serum concentrations of testosterone and 17 alpha-hydroxyprogesterone. Clin Chem. 1992;38:1779–1784.PubMedGoogle Scholar
  12. Catlin DH. Androgen abuse by athletes. In: Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C. Kelly C. Eds. International Androgen Workshop (2nd): Pharmacology, Biology, and Clinical Applications of Androgens: current status and future prospects. Wiley-Liss, Inc., New York, 1995;289–300.Google Scholar
  13. Catlin DH, Cowan DA. Detecting testosterone administration. Clin Chem. 1992;38:1685–1686.PubMedGoogle Scholar
  14. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic enhancement. Adv Int Med. 1990;36:381–405.Google Scholar
  15. Catlin DH, Murray TH. Performance-enhancing drugs, fair competition, and Olympic sport. JAMA. 1996;276:231–237.PubMedCrossRefGoogle Scholar
  16. Catlin DH, Hatton CK, Starcevic SH. Issues in detecting abuse of xenobiotic anabolic steroids by analysis of athletes’ urine. Clin Chem. 1997;43:1280–1288.PubMedGoogle Scholar
  17. Catlin DH, Cowan DA, de la Torre R, Donike M, Fraisse D, Oftebro H, Hatton CK, et al. Urinary testosterone (T) to epitestosterone (E) ratios by GC/MS. I. Initial comparison of uncorrected T/E in six international laboratories. J Mass Spectrometry 1996;31:397–402.CrossRefGoogle Scholar
  18. Committee on the Judiciary, United States Senate. Hearings before the Subcommittee to investigate juvenile deliquency, June 6. Cooper DL. Drugs and the athlete. JAMA. 1972;221:1007–1011.CrossRefGoogle Scholar
  19. Committee on the Judiciary, GAO Report to the Chairman, U.S. Senate. Drug Misuse: Anabolic Steroids and Human Growth Hormone. August, 1989.Google Scholar
  20. Council on Scientific Affairs. Drug Abuse in Athletes: Anabolic steroids and Human Growth Hormone. JAMA 1988;259:1703–1705.CrossRefGoogle Scholar
  21. Cowan DA, Kicman AT, Walker CJ et al. Effect of administration of human chorionic gonadotrophin on criteria used to assess testosterone administration in athletes. J Endocrinol. 1991;131:147–154.PubMedGoogle Scholar
  22. Courts SB, Kicman AT, Hurst DT, Cowan DA. Intramuscular administration of 5 alpha-dihydrotestosterone heptanoate: changes in urinary hormone profile. Clin Chem. 1997;43:2091–2098.Google Scholar
  23. Dehennin L. Detection of simultaneous self-administration of testosterone and epitestosterone in healthy men. Clin Chem. 1994a;40:106–109.PubMedGoogle Scholar
  24. Dehennin L. On the origin of physiologically high ratios of urinary testosterone to epitestosterone: consequences for reliable detection of testosterone administration by male athletes. J Endocrinol 1994b;142:353–360.PubMedGoogle Scholar
  25. Dehennin L, Peres G. Plasma and urinary markers of oral testosterone misuse by healthy men in presence of masking epitestosterone administration. Int J Sports Med. 1996;17:315–319.PubMedCrossRefGoogle Scholar
  26. Dehennin L, Matsumoto AM. Long-term administration of testosterone enanthate to normal men: alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport. J Steroid Biochem Mol Biol. 1993;44:179–189.PubMedCrossRefGoogle Scholar
  27. Dehennin L, Ferry M, Lafarge P, Peres G, Lafarge JP. Oral administration of dehydroepiandrosterone to healthy men: alteration of the urinary androgen profile and consequences for the detection of abuse in sport by gas chromatography-mass spectrometry. Steroids 1998; 63:80–87.PubMedCrossRefGoogle Scholar
  28. Donike M, Rauth S, Mareck-Engelke U, Geyer H, Nitschke R. Evaluation of longitudinal studies, the determination of subject based reference ranges of the testosterone / epitestosterone ratio. In: Donike M, Geyer H, Gotzmann, eds. Proceedings of the 11th Cologne workshop on dope analysis, 7-12 March 1993. Edition Sport, Köln: Sport und Buch Strauss, 1994;33–39.Google Scholar
  29. Donike M, Barwald KR, Klostermann K, Schänzer W, Zimmermann J, Nachweis von exogenem Testosteron (The Detection of Exogenous Testosterone), in H. Heck W. Hollmann, H. Liesen. eds, Sport: Leistung und Gesundheit, eds, Köln, Germany, Kongressbd. Dtsch. Sportarztekongress, Deutscher Ärzte-Verlag, 1983;pp293–298.Google Scholar
  30. Donike M, Ueki M, Kuroda Y, Geyer H, Nolteernsting E, Rauth S, et al. Detection of dihydrotestosterone (DHT) doping: alterations in the steroid profile and reference ranges for DHT and its 5 alpha-metabolites [editorial]. J Sports Med Phys Fitness 1995;35:235–250.PubMedGoogle Scholar
  31. Falk O, Palonek E, Bjorkhem I. Effect of ethanol on the ratio between testosterone and epitestosterone in urine. Clin Chem. 1988;34:462–1464.Google Scholar
  32. Garle M, Ocka R, Palonek E, Björkhem I. Increased urinary testosterone / epitestosterone ratios found in Swedish athletes in connection with a national control program evaluation of 28 cases. J Chromat B 1996;687:55–59.CrossRefGoogle Scholar
  33. Geyer H, Schänzer W, Mareck-Engelke U, Donike M. Stability of steroid profiles (5): The annual rhythm of urinary ratios and excretion rates of endogenous steroids in female and its menstrual dependency. In: Donike M, Geyer H, Gotzmann, eds. Proceedings of the 13th Cologne workshop on dope analysis (3), 12–17 April 1995. Edition Sport, Köln: Sport und Buch Strauss, 1996;177–190.Google Scholar
  34. Horton R, Rosner JM, Forsham PH. Urinary excretion pattern of injected H3-testosterone. Proc Soc Exp Biol Med. 1963;114:400–403.PubMedGoogle Scholar
  35. Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest. 1966;45:301–313.PubMedCrossRefGoogle Scholar
  36. IOC Medical Commission, meeting Feb 1982.Google Scholar
  37. IOC Medical Code. International Olympic Committee. Lausanne, Switzerland, 1995. (ISBN 92-9149-003-2)Google Scholar
  38. Karila T, Kosunen V, Leinonen A, Tahtela R, Seppala T. High doses of alcohol increase urinary testosterone-to-epitestosterone ratio in females. J Chromatogr B Biomed.Appl. 1996; 687:109–116.PubMedCrossRefGoogle Scholar
  39. Kicman AT, Brooks RV, Collyer SC, Cowan DA, Nanjee MN, Southan GJ, Wheeler M. Criteria to indicate testosterone administration. Br J Sports Med. 1990;24:253–264.PubMedGoogle Scholar
  40. Kicman AT, Courts SB, Walker CJ, Cowan DA. Proposed confirmatory procedure for detecting 5 alpha-dihydrotestosterone doping in male athletes. Clin.Chem. 1995;41:1617–1627.PubMedGoogle Scholar
  41. Kicman AT, Oftebro H, Walker C, Norman N, Cowan DA. Potential use of ketoconazole in a dynamic endocrine test to differentiate between biological outliers and testosterone use by athletes. Clin Chem. 1993;39:798–1803.Google Scholar
  42. Lantto O, Bjorkhem I, Ek H, Johnston D. Detection and quantitation of stanozolol (Stromba) in urine by isotope dilution-mass fragmentography. J Steroid Biochem. 1981;14:721–727.PubMedCrossRefGoogle Scholar
  43. Longcope C. Dehydroepiandrosterone metabolism. J Endocrinol. 1996;150 Suppl:S125–7.Google Scholar
  44. Namba O, Miyachi, Kawahara M, Kuroda, I, Kuroda Y. Urinary testosterone and epitestosterone secretion in a doping positive subject. In: Laron Z, Rogol AD. eds., Hormones and Sport. Serono Symposia Publications. 1989:275–283.Google Scholar
  45. Oftebro H. Evaluating an abnormal urinary steroid profile. Lancet 1992;339:941–942.PubMedCrossRefGoogle Scholar
  46. Oftebro H, Jensen J, Mowinckel P, Norli HR. Establishing a ketoconazole suppression test for verifying testosterone administration in the doping control of athletes. J Clin Endocrinol Metab. 1994;78:973–977.PubMedCrossRefGoogle Scholar
  47. Perry PJ, MacIndoe JH, Yates WR, Scott SD, Holman TL. Detection of anabolic steroid administration: ratio of urinary testosterone to epitestosterone vs the ratio of urinary testosterone to luteinizing hormone. Clin Chem. 1997;43:731–735.PubMedGoogle Scholar
  48. Raynaud E, Audran M, Brun JF, Fedou C, Chanal JL, Orsetti A. False-positive cases in detection of testosterone doping. Lancet 1992;340:1468–1469.PubMedCrossRefGoogle Scholar
  49. Shackleton CH, Phillips A, Chang T, Li Y. Confirming testosterone administration by isotope ratio mass spectrometric analysis of urinary androstanediols. Steroids 1997b;62:379–387.PubMedCrossRefGoogle Scholar
  50. Shackleton CH, Roitman E, Phillips A, Chang T. Androstanediol and 5-androstenediol profiling for detecting exogenously administered dihydrotestosterone, epitestosterone, and dehydroepiandrosterone: potential use in gas chromatography isotope ratio mass spectrometry. Steroids 1997a;62:665–673.PubMedCrossRefGoogle Scholar
  51. Southan G, Mallet A, Jumeau J, Craig S, Poojara N, Micchjell D, Wheeler M, Brooks R. in Programme and Abstracts of the Second Internationa Symposium on Applied Mass Spectrometry in the Health Sciences. Barcelona 1990. P. 306.Google Scholar
  52. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996; 42:1001–1020.PubMedGoogle Scholar
  53. Schänzer W., Opfermann G., and Donike M. Metabolism of stanozolol: identification and synthesis of urinary metabolites. J Steroid Biochem. 1990;36:153–174.PubMedCrossRefGoogle Scholar
  54. Schänzer W, Donike, M. Metabolism of boldenone in man: gas chromatographic/mass spectrometric identification of urinary excreted metabolites and determination of excretion rates. Biol Mass Spectrom. 1992;21:3–16.PubMedCrossRefGoogle Scholar
  55. Schänzer W, Delahaut P, Geyer H, Machnik M, Horning S. Longterm detection and identification of metandienone and stanozolol abuse in athletes by gas chromatography-high-resolution mass spectrometry. J Chromatog B 1996;687:93–108.CrossRefGoogle Scholar
  56. Wilson JD. Androgen abuse by athletes. Endocrine Reviews 1988;9:181–199.PubMedCrossRefGoogle Scholar
  57. Wilson JD, Griffin JE. The use and misuse of androgens. Metabolism 1982;29:1278–1295.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • D. H. Catlin
    • 1
  1. 1.UCLA Olympic Analytical LaboratoryLos Angeles

Personalised recommendations